LuShun Zhang1, Ling Hu2, Xin Li3, Jing Zhang4, Bo Chen5. 1. Department of Pathology and Pathophysiology, Cheng Du Medical College, Chengdu 610500, China. Electronic address: zhangls2012@163.com. 2. Department of Pathology, Chongqing Three Gorges Medical College, Chongqing 404120, China. Electronic address: huling0511@126.com. 3. Basic Medical College, Cheng Du Medical College, Chengdu 610500, China. Electronic address: bluesky918@aliyun.com. 4. Department of Pathology, First Hospital of Lanzhou University, Lanzhou 730000, China. Electronic address: bigzebrafish@163.com. 5. The Cadre Ward Fourth Ward, People׳s Liberation Army General Hospital of Chengdu Military Region, Chengdu 610083, China. Electronic address: softwind123@163.com.
Abstract
BACKGROUND: Growing studies have revealed the association between rs1800497 polymorphism in the dopamine receptor D2 (DRD2) and susceptibility to mood disorder (MD). However, the results remained inconsistent. METHODS: To assess the effect of DRD2 rs1800497 polymorphism on MD. We performed a meta-analysis based on eight case-control studies, including a total of 2097 MD cases and 1681 controls. Summary odds ratios (OR) and corresponding 95% confidence intervals (CIs) for DRD2 rs1800497 polymorphism and MD risk were estimated. RESULTS: Our meta-analysis indicated that DRD2 rs1800497 was associated with an increased MD risk, especially in Asians. Moreover, in the subgroup analysis by the type of MD, DRD2 rs1800497 polymorphism was observed to increase risk in BP. LIMITATIONS: The results should be treated with caution for lacking of data to perform gene-gene and gene-environment interaction. CONCLUSIONS: Our results indicated that polymorphism in DRD2 rs1800497 may play a role in development of MD.
BACKGROUND: Growing studies have revealed the association between rs1800497 polymorphism in the dopamine receptor D2 (DRD2) and susceptibility to mood disorder (MD). However, the results remained inconsistent. METHODS: To assess the effect of DRD2rs1800497 polymorphism on MD. We performed a meta-analysis based on eight case-control studies, including a total of 2097 MD cases and 1681 controls. Summary odds ratios (OR) and corresponding 95% confidence intervals (CIs) for DRD2rs1800497 polymorphism and MD risk were estimated. RESULTS: Our meta-analysis indicated that DRD2rs1800497 was associated with an increased MD risk, especially in Asians. Moreover, in the subgroup analysis by the type of MD, DRD2rs1800497 polymorphism was observed to increase risk in BP. LIMITATIONS: The results should be treated with caution for lacking of data to perform gene-gene and gene-environment interaction. CONCLUSIONS: Our results indicated that polymorphism in DRD2rs1800497 may play a role in development of MD.
Authors: Diana R Samek; Jennifer Bailey; Karl G Hill; Sylia Wilson; Susanne Lee; Margaret A Keyes; Marina Epstein; Andrew Smolen; Michael Miller; Ken C Winters; J David Hawkins; Richard F Catalano; William G Iacono; Matt McGue Journal: Behav Genet Date: 2016-07-21 Impact factor: 2.805
Authors: Anni Richter; Marc Guitart-Masip; Adriana Barman; Catherine Libeau; Gusalija Behnisch; Sophia Czerney; Denny Schanze; Anne Assmann; Marieke Klein; Emrah Düzel; Martin Zenker; Constanze I Seidenbecher; Björn H Schott Journal: Front Syst Neurosci Date: 2014-08-06
Authors: Kenneth Blum; Marcelo Febo; Thomas McLaughlin; Frans J Cronjé; David Han; S Mark Gold Journal: J Behav Addict Date: 2014-08-26 Impact factor: 6.756
Authors: Anna Michalczyk; Justyna Pełka-Wysiecka; Jolanta Kucharska-Mazur; Michał Wroński; Błażej Misiak; Jerzy Samochowiec Journal: Ann Gen Psychiatry Date: 2020-06-17 Impact factor: 3.455
Authors: Dawn Kingston; Muhammad K Mughal; Muhammad Arshad; Igor Kovalchuk; Gerlinde A S Metz; Katherine Wynne-Edwards; Suzanne King; Shui Jiang; Lynne Postovit; Abdul Wajid; Sheila McDonald; Donna M Slater; Suzanne C Tough; Katherine Aitchison; Paul Arnold Journal: Front Psychiatry Date: 2019-10-31 Impact factor: 4.157